1Schulman SL. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. The Journal of Pediatrics, 1988,113(6) :996 - 1001.
3Mraee A, Peer G, Schwartz, et al. Role of nitric oxide in glycerol-induced acute renal failure in rats. Nephrol Dial Transplant, 1994,9 (Suppl 4): 78.
4Noiri E, Peresleni T, Srivastava N, et al. Nitric oxide is necessary for a swith from stationary to locomoting phenotype in epithelial cells. Am J Physiol, 1996,270: 794.
5Ohta K, Hirata Y, Shichiri M, et al. Urinary execretion of endothelin-l in normal subjects and patients with renal disease. Kidney I nt, 1991,39:307-315.
6Hocher B, Thue Reineke C, Rohmeiss P, et al. Endothelinl transgenic mice develop glomerulosclerosis, interstitial fibrosis,and renal cysts but not hypertension. J Clin Invest, 1997,99(6), 1380-1389.
7Bruzzi I,Corna D,Zoja C,et al. Time course and localization of endothelin-1 gene expression in a model of renal disease progression. Am J Pathol, 1997,151 (5): 1241-1249.
8Reslerova M, Loutzenh iser R. Renal microvascular actions of calcitonin gene-related peptide. Am J Physiol , 1998,274(6 Pt 2) :F1078-1085.
9Benigi A, Zoja C, Corna D, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal diseases progression. Kidney Int, 1993,44: 440-446.
10Palla R, Parrini M, Panichi V, et al. Acute effects of calcitonin gene related peptide on renal haemodynamics and renin and angiotensin Ⅱ secretion in patients with renal disease. Int J Tissue React, 1995,17( 1 ): 43-49.
